ganfort
abbvie deutschland gmbh & co. kg - bimatoprosto, timololio - glaucoma, open-angle; ocular hypertension - oftalmologai - intraokulinio slėgio (iop) sumažėjimas pacientams, kuriems yra atvirojo kampo glaukoma arba akių hipertenzija, kurie nepakankamai reaguoja į vietinius beta adrenoblokatorius ar prostaglandino analogus.
haemoctin sdh
biotest pharma gmbh - Žmogaus viii koaguliacijos faktorius - milteliai ir tirpiklis injekciniam tirpalui - 1000 tv; 500 tv; 250 tv - coagulation factor viii
atimos
chiesi pharmaceuticals gmbh - formoterolio fumaratas dihidratas - suslėgtasis įkvepiamasis tirpalas - 12 µg/dozėje - formoterol
enstilar
leo pharma a/s - kalcipotriolis/betametazonas - odos putos - 50 µg/0,5 mg/g - calcipotriol, combinations
foster
chiesi pharmaceuticals gmbh - beklometazono dipropionatas/formoterolio fumaratas dihidratas - įkvepiamieji milteliai - 100 µg/6 µg/išpurškime; 200 µg/6 µg/išpurškime - formoterol and beclometasone
foster
chiesi pharmaceuticals gmbh - beklometazono dipropionatas/formoterolio fumaratas dihidratas - įkvepiamieji milteliai - 200 µg/12 µg/dozėje - formoterol and beclometasone
ranivisio
midas pharma gmbh - ranibizumabas - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmologai - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).
hyftor
plusultra pharma gmbh - sirolimus - angiofibroma; tuberous sclerosis - hyftor is indicated for the treatment of facial angiofibroma associated with tuberous sclerosis complex in adults and paediatric patients aged 6 years and older.
filsuvez
amryt pharmaceuticals dac - dry extract from birch bark (der 5-10 : 1), extraction solvent n-heptane 95% (w/w) - epidermolysis bullosa dystrophica; epidermolysis bullosa, junctional - preparatai žaizdų ir opų gydymui - treatment of partial thickness wounds associated with dystrophic and junctional epidermolysis bullosa (eb) in patients 6 months and older.
calgonit des he.
calvatis gmbh, dr.-albert-reimann-str. 16 a, de-68526 ladenburg (vokietija). - etanolis, etilo alkoholis - veikliosios medžiagos cas nr.: 64-17-5, eb nr.: 200-578-6, veikliosios medžiagos pavadinimas: etanolis, etilo alkoholis, koncentracija: 74.5% , veiklioji - asmens higiena